Recent blog posts
NCT07617948 Aminophylline Calculus, Ureteral Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07617948 Aminophylline Calculus, Ureteral Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07617948 clinical trial report covering Aminophylline, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07616453 Culmerciclib ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616453 Culmerciclib ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616453 clinical trial report covering Culmerciclib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07617909 L-Citrulline Calculus, Ureteral Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07617909 L-Citrulline Calculus, Ureteral Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07617909 clinical trial report covering L-Citrulline, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07617922 Melatonin Calculus, Ureteral Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07617922 Melatonin Calculus, Ureteral Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07617922 clinical trial report covering Melatonin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07617896 Aminophylline Calculus, Ureteral Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07617896 Aminophylline Calculus, Ureteral Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07617896 clinical trial report covering Aminophylline, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07616427 Trastuzumab HR-positive/HER2-low Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616427 Trastuzumab HR-positive/HER2-low Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616427 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07618910 Albumin-Bound Paclitaxel Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07618910 Albumin-Bound Paclitaxel Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07618910 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07616141 Anlotinib Dihydrochloride Adenoid Cystic Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616141 Anlotinib Dihydrochloride Adenoid Cystic Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616141 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07618923 Trastuzumab Rezetecan HR-positive/HER2-low Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07618923 Trastuzumab Rezetecan HR-positive/HER2-low Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07618923 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07618390 Fulvestrant PIK3CA mutation/HR-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07618390 Fulvestrant PIK3CA mutation/HR-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07618390 clinical trial report covering Fulvestrant, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600125865 Bevacizumab Recurrent Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600125865 Bevacizumab Recurrent Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
ChiCTR2600125865 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07617324 Stapokibart Rhinitis, Allergic, Seasonal Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07617324 Stapokibart Rhinitis, Allergic, Seasonal Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07617324 clinical trial report covering Stapokibart, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →